Bossenkinney4422

Physical inactivity is one major modifiable risk factor for dementia (especially Alzheimer's disease). Due to contact restrictions and isolation measures in response to the current COVID-19 (coronavirus disease 2019) pandemic, physical inactivity levels have increased by up to 30%, which will likely have adverse consequences for primary and secondary dementia prevention. Therefore, new interdisciplinary prevention approaches (eg, outdoor exercise; app-based exercise with online partners) are urgently needed that account for the suspected long-term lifestyle changes that the current-and upcoming-pandemics are likely to entail (increased use of home office, social isolation, avoidance of fitness centers and club sports, and so on).As knowledge of Alzheimer's disease (AD) progression improves, the field has recognized the need to diversify the pipeline, broaden strategies and approaches to therapies, as well as delivery mechanisms. A better understanding of the earliest biological processes of AD/dementia would help inform drug target selection. Currently there are a number of programs exploring these alternate avenues. This meeting will allow experts in the field (academia, industry, government) to provide perspectives and experiences that can help elucidate what the pipeline looks like today and what avenues hold promise in developing new therapies across the stages of AD. The focus here is on Active Immunotherapies and Alternative Therapeutic Modalities. This topic includes active vaccines, antisense oligomers, and cell-based therapy among others, and highlights new clinical developments that utilize these modalities.

Cognitive decline in Alzheimer's disease is associated with amyloid beta (Aβ) accumulation, neurodegeneration, and cerebral small vessel disease, but the temporal relationships among these factors is not well established.

Data included white matter hyperintensity (WMH) load, gray matter (GM) atrophy and Alzheimer's Disease Assessment Scale-Cognitive-Plus (ADAS13) scores for 720 participants and cerebrospinal fluid amyloid (Aβ1-42) for 461 participants from the Alzheimer's Disease Neuroimaging Initiative. Linear regressions were used to assess the relationships among baseline WMH, GM, and Aβ1-42 to changes in WMH, GM, Aβ1-42, and cognition at 1-year follow-up.

Baseline WMHs and Aβ1-42 predicted WMH increase and GM atrophy. Baseline WMHs and Aβ1-42 predicted worsening cognition. Only baseline Aβ1-42 predicted change in Aβ1-42.

Baseline WMHs lead to greater future GM atrophy and cognitive decline, suggesting that WM damage precedes neurodegeneration and cognitive decline. Baseline Aβ1-42 predicted WMH increase, suggesting a potential role of amyloid in WM damage.

Baseline WMHs lead to greater future GM atrophy and cognitive decline, suggesting that WM damage precedes neurodegeneration and cognitive decline. Baseline Aβ1-42 predicted WMH increase, suggesting a potential role of amyloid in WM damage.Childhood economic conditions are important for adult health, and welfare regimes may modify this relationship by altering exposure to social determinants of health. We examine the association between childhood economic stress (CES) and self-rated health (SRH) and cancer (any type), and how welfare regimes may influence these associations. We used data from European Social Survey round 7. Our study is based on 30 024 individuals between 25 to 75 years from 20 European countries grouped into five welfare regimes (Scandinavian, Anglo-Saxon, Bismarckian, Southern and Eastern). Multilevel models were used to assess the association between CES and SRH/cancer, and interactions between CES and welfare regimes. CES increased the risk of poor SRH (RR 1.41, 95% CI 1.29-1.54) and cancer (RR 1.19, 95% CI 1.02-1.37). Controlling for adult socioeconomic status slightly reduced risk for poor SRH, but not cancer. Selinexor molecular weight CES increased the probability of poor SRH in the Southern and Eastern regime, and the probability of cancer in the Anglo-Saxon regime, relative to the Scandinavian regime. Childhood economic stress increases the risk of poor self-rated health and cancer. More comprehensive welfare states mitigate these associations, which emphasizes the impact of welfare policies on long-term health outcomes of childhood economic conditions.[This corrects the article DOI 10.1016/j.ijpam.2019.05.006.][This corrects the article DOI 10.1016/j.ijpam.2019.11.002.][This corrects the article DOI 10.1016/j.ijpam.2018.01.004.][This corrects the article DOI 10.1016/j.ijpam.2019.10.004.][This corrects the article DOI 10.1016/j.ijpam.2019.05.001.][This corrects the article DOI 10.1016/j.ijpam.2020.03.004.][This corrects the article DOI 10.1016/j.ijpam.2019.07.004.][This corrects the article DOI 10.1016/j.ijpam.2020.02.004.][This corrects the article DOI 10.1016/j.ijpam.2019.04.002.][This corrects the article DOI 10.1016/j.ijpam.2019.01.002.][This corrects the article DOI 10.1016/j.ijpam.2020.07.001.][This corrects the article DOI 10.1016/j.ijpam.2019.07.007.][This corrects the article DOI 10.1016/j.ijpam.2018.06.001.][This corrects the article DOI 10.1016/j.ijpam.2020.01.007.].Agonists of the co-stimulatory molecule OX40 (CD134) are in clinical assessment alone and in combination with other immunotherapies. Recent pre-clinical studies have suggested that concurrent administration of OX40 agonists with anti-PD1 therapy is detrimental to the efficacy of such combinations and maximal efficacy may require sequential administration of the OX40 agonist followed by anti-PD1 therapy. In this report, we detail two patients with advanced ovarian carcinoma were treated with INCAGN01949, an agonistic OX40 Ab, as part of a clinical trial until disease progression. Both patients then received the combination of ipilimumab and nivolumab and experienced unusually deep and durable responses. These cases support the hypothesis raised in pre-clinical studies and highlight the potential relevance of sequence in combinational immunotherapy.

There is no consensus regarding superiority between gap balancing (GB) and measured resection (MR) techniques to implant total knee arthroplasties. In a multicenter setup, we compared both techniques using the same prosthesis.

We included 262 balanSys posterior-stabilized total knee arthroplasties from 4 centers 3 using the MR (n= 162) and one using the GB technique (n= 100), without navigation.

There was no significant difference in the Knee Society Score or visual analog scale pain at 2- and 7-year follow-up. The visual analog scale for satisfaction was significantly better in the MR group at 2 but not at 7 years. We found a significantly higher average valgus in the GB group, but the overall alignment was within 2° of neutral on the full-leg radiographs. There were no significant differences concerning radiolucency and survival.

We found no significant differences in the functional outcome, pain, alignment, or survival, but a tendency toward better function using MR and better survival with GB.

We found no significant differences in the functional outcome, pain, alignment, or survival, but a tendency toward better function using MR and better survival with GB.